Ha-Ram Park, Shawn J Kim, Nashat Zaman, Nika P Kozlov, Somnath Tagore, Lawrence W Wu, Benjamin Izar, Minah Kim
{"title":"Spatial polarization of endothelial ICAM-1 governs T-cell exclusion in melanoma.","authors":"Ha-Ram Park, Shawn J Kim, Nashat Zaman, Nika P Kozlov, Somnath Tagore, Lawrence W Wu, Benjamin Izar, Minah Kim","doi":"10.1038/s44321-026-00542-1","DOIUrl":null,"url":null,"abstract":"<p><p>An immunosuppressive microenvironment limits therapeutic efficacy in melanoma. Beyond T-cell abundance and function, tumor control depends on T-cell access to malignant cells, yet the vascular mechanisms governing T-cell positioning remain poorly defined. Using RNA sequencing of endothelial cells from tumor cores versus peripheries in a mouse melanoma model, we identified intercellular adhesion molecule-1 (ICAM-1) as a candidate regulator of T-cell localization. During tumor growth, T cells shifted from a balanced core-margin distribution to marked exclusion from the core, particularly in T cell-inflamed tumors. This spatial polarization, less evident in other immune subsets, coincided with high expression of lymphocyte function-associated antigen-1 (LFA-1) on T cells. Endothelial ICAM-1 became enriched at the tumor periphery, where vascular integrity was compromised, with increased vascular leakage and reduced pericyte coverage. ICAM-1 blockade restored T-cell infiltration, enhanced effector activity, and delayed growth of immunogenic tumors, and sensitized an immune-refractory tumor to anti-PD-1 blockade. These findings identify endothelial ICAM-1 as a vascular determinant of T-cell positioning and the ICAM-1/LFA-1 axis as a modifiable checkpoint to enhance antitumor immunity and immunotherapy efficacy.</p>","PeriodicalId":11597,"journal":{"name":"EMBO Molecular Medicine","volume":" ","pages":""},"PeriodicalIF":7.9000,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMBO Molecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s44321-026-00542-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
An immunosuppressive microenvironment limits therapeutic efficacy in melanoma. Beyond T-cell abundance and function, tumor control depends on T-cell access to malignant cells, yet the vascular mechanisms governing T-cell positioning remain poorly defined. Using RNA sequencing of endothelial cells from tumor cores versus peripheries in a mouse melanoma model, we identified intercellular adhesion molecule-1 (ICAM-1) as a candidate regulator of T-cell localization. During tumor growth, T cells shifted from a balanced core-margin distribution to marked exclusion from the core, particularly in T cell-inflamed tumors. This spatial polarization, less evident in other immune subsets, coincided with high expression of lymphocyte function-associated antigen-1 (LFA-1) on T cells. Endothelial ICAM-1 became enriched at the tumor periphery, where vascular integrity was compromised, with increased vascular leakage and reduced pericyte coverage. ICAM-1 blockade restored T-cell infiltration, enhanced effector activity, and delayed growth of immunogenic tumors, and sensitized an immune-refractory tumor to anti-PD-1 blockade. These findings identify endothelial ICAM-1 as a vascular determinant of T-cell positioning and the ICAM-1/LFA-1 axis as a modifiable checkpoint to enhance antitumor immunity and immunotherapy efficacy.
期刊介绍:
EMBO Molecular Medicine is an open access journal in the field of experimental medicine, dedicated to science at the interface between clinical research and basic life sciences. In addition to human data, we welcome original studies performed in cells and/or animals provided they demonstrate human disease relevance.
To enhance and better specify our commitment to precision medicine, we have expanded the scope of EMM and call for contributions in the following fields:
Environmental health and medicine, in particular studies in the field of environmental medicine in its functional and mechanistic aspects (exposome studies, toxicology, biomarkers, modeling, and intervention).
Clinical studies and case reports - Human clinical studies providing decisive clues how to control a given disease (epidemiological, pathophysiological, therapeutic, and vaccine studies). Case reports supporting hypothesis-driven research on the disease.
Biomedical technologies - Studies that present innovative materials, tools, devices, and technologies with direct translational potential and applicability (imaging technologies, drug delivery systems, tissue engineering, and AI)